Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Indiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 31 | 1,276 | 35% |
| 2020 | 22 | 1,115 | 39% |
| 2021 | 20 | 1,072 | 44% |
| 2022 | 17 | 955 | 47% |
| 2023 | 20 | 1,049 | 51% |
| 2024 | 21 | 997 | 53% |
| 2025 from claims | – | 948 767–1,114 | 54% |
| 2026 forecast | – | 955 748–1,199 | 55% |
| 2027 forecast | – | 957 710–1,266 | 55% |
| 2028 forecast | – | 960 680–1,325 | 56% |
| 2029 forecast | – | 962 654–1,380 | 57% |
| 2030 forecast | – | 965 632–1,431 | 57% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 57% of the cases CMS names in Indiana; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 50% inpatient hospital, 47% hospital outpatient, 3% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 25 | 1,738−4.6%/yr | −4.6%/yr | 1.5 | 5% | 1,920 in 2030+1.7%/yr |
| Illinois | 28 | 1,515−7.1%/yr | −7.1%/yr | 1.1 | 2% | 1,670 in 2030+1.6%/yr |
| Michigan | 24 | 1,338−6.2%/yr | −6.2%/yr | 1.5 | 3% | 1,110 in 2030−3%/yr |
| Missouri | 25 | 1,166−5.8%/yr | −5.8%/yr | 1.8 | 1% | 1,250 in 2030+1.1%/yr |
| Minnesota | 9 | 723−4.6%/yr | −4.6%/yr | 1.5 | 0% | 840 in 2030+2.4%/yr |
| Kansas | 11 | 616−1.8%/yr | −1.8%/yr | 1.5 | 0% | 710 in 2030+2.5%/yr |
| Wisconsin | 3 | 479−5.3%/yr | −5.3%/yr | 0.8 | 4% | 730 in 2030+7.3%/yr |
| Iowa | 9 | 408+2.6%/yr | +2.6%/yr | 0.9 | 3% | 500 in 2030+3.4%/yr |
| Nebraska | 8 | 406−2.1%/yr | −2.1%/yr | 1.5 | 6% | 480 in 2030+2.7%/yr |
| South Dakota | 4 | 201−1.4%/yr | −1.4%/yr | 1.5 | 0% | 270 in 2030+4.8%/yr |
| North Dakota | 3 | 152−5.1%/yr | −5.1%/yr | 1.5 | 0% | 160 in 2030+0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 65 | 2,388−6%/yr | −6%/yr | 3.31.1× | 5% | 2,460 in 2030+0.5%/yr |
| Lumbar fusion | 65 | 2,274−3.7%/yr | −3.7%/yr | 3.11.2× | 0% | 2,210 in 2030−0.5%/yr |
| Kyphoplasty & vertebroplasty | 13 | 1,180−9.3%/yr | −9.3%/yr | 1.61.2× | 19% | 1,300 in 2030+1.7%/yr |
| SI joint fusion | 3 | 192+9%/yr | +9%/yr | 0.21.2× | 27% | 430 in 2030+14%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Indiana · Every state · Compare with Ohio
Globus Medical leads with 47% of company spending on these surgeons in 2025, +22 pts on 2024.
In 2025, 15 companies reported engagement with Indiana’s surgeons worth $97K in consulting, speaking, meals and travel tied to these products, about $4,610 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.